Is it safe to prescribe atomoxetine (Strattera) to a patient with bipolar disorder who is on a mood stabilizer?

Atomoxetine in Bipolar Disorder with Mood Stabilizer Coverage

Atomoxetine (Strattera) can be prescribed to patients with bipolar disorder who are on mood stabilizers, but requires close monitoring for mood destabilization, as the FDA label specifically warns about screening for bipolar disorder and the risk of inducing manic/mixed episodes. 1

Key FDA Warning and Prescribing Considerations

The FDA label for Strattera explicitly states: "In general, particular care should be taken in treating ADHD in patients with comorbid bipolar disorder because of concern for possible induction of a mixed/manic episode in patients at risk for bipolar disorder" 1. This warning emphasizes that:

• Patients with comorbid depressive symptoms should be adequately screened for bipolar disorder risk before initiating atomoxetine
• Treatment-emergent psychotic or manic symptoms (hallucinations, delusional thinking, mania) can occur at usual doses 1
• If such symptoms emerge, discontinuation should be considered 1

Clinical Evidence: Mixed Results

The research evidence presents a nuanced picture:

Supportive evidence:

• A 2005 case series showed 6 of 7 pediatric bipolar patients on mood stabilizers had significant ADHD improvement with atomoxetine, with no hypomanic/manic episodes 2
• An 8-week open-label study found 67% response rate in euthymic youth with bipolar disorder on mood stabilizers, though 2 of 12 subjects discontinued due to worsening mood symptoms 3
• A 2015 review concluded atomoxetine may be effective with "modestly increased risk" of (hypo)manic switches when used with mood stabilizers 4

Cautionary evidence:

• A 2017 case report documented atomoxetine-induced hypomania in a stabilized bipolar patient on prophylactic mood stabilizers, demonstrating that risk exists even in well-controlled patients 5

Practical Clinical Algorithm

Step 1: Ensure mood stability

• Patient must be euthymic on current mood stabilizer regimen
• Confirm adequate mood stabilizer levels/dosing
• No recent mood episodes in past 2-3 months

Step 2: Initiate with caution

• Start atomoxetine at standard weight-based dosing (target 1.4 mg/kg/day or 100 mg/day maximum) 6
• Continue all mood stabilizers without interruption

Step 3: Intensive monitoring protocol

• Weekly visits for first month to assess for emergent manic symptoms (decreased need for sleep, increased energy, racing thoughts, impulsivity)
• Monitor for psychotic symptoms (hallucinations, delusional thinking) 1
• Assess for irritability, agitation, or aggressive behavior 1
• Continue monitoring every 2 weeks for months 2-3

Step 4: Discontinuation criteria

• Any emergence of hypomanic/manic symptoms → stop atomoxetine immediately
• New psychotic symptoms → discontinue and reassess
• Significant mood destabilization → halt treatment

Critical Pitfalls to Avoid

1. Do not prescribe atomoxetine during active mood episodes - patient must be euthymic first
2. Never reduce or discontinue mood stabilizers when adding atomoxetine
3. Do not assume safety based on mood stabilizer coverage alone - the 2017 case report proves breakthrough hypomania can occur 5
4. Avoid inadequate monitoring - the first 4-8 weeks are highest risk for mood destabilization

Additional Safety Considerations

Beyond mood destabilization, monitor for:

• Suicidal ideation (FDA black box warning in youth) 1
• Blood pressure and heart rate changes (mean increases of 2-4 mmHg and 6-8 bpm) 1
• Cardiovascular effects may be more pronounced in poor metabolizers (7% of population) 6

The hierarchical approach is essential: stabilize mood disorder first, then cautiously address ADHD symptoms with atomoxetine while maintaining vigilant monitoring for mood destabilization. 4